Table 5.
Comparison of blood indicators and VEGF-A between the two groups before and after treatment.
| Indicators | Arms | Before the treatment | After treatment | Z/t | P value | |
|---|---|---|---|---|---|---|
| Routine indexes (Unit) | WBC (x 109/L) | Control | *5.29 (3.89, 6.7) | *4.11 (3.09, 4.64) | 3.592 | <0.001 |
| Experimental | ^4.230 ± 1.67 | ^4.70 ± 2.11 | 1.029 | 0.309 | ||
| HB (g/L) | Control | *111.00 (102.00, 122.00) | *106.00 (100.00, 116.00) | 3.177 | 0.001 | |
| Experimental | ^113.02 ± 15.68 | ^107.00 ± 12.64 | 3.092 | 0.003 | ||
| PLT (x 109/L) | Control | ^244.00 ± 103.84 | ^184.62 ± 70.25 | 4.226 | <0.001 | |
| Experimental | ^174.52 ± 63.16 | ^158.60 ± 51.98 | 1.684 | 0.099 | ||
| ALB (g/L) | Control | *41.20 (38.10, 42.70) | *39.90 (37.10, 42.60) | 1.357 | 0.175 | |
| Experimental | *42.75 (40.25, 44.85) | *41.40 (38.05, 43.60) | 2.101 | 0.36 | ||
| Tumor indexes (Unit, reference value) | SCC (ng/L, 0-3.00) | Control | *4.45 (2.17, 8.20) | *1.72 (0.80, 5.10) | 3.900 | <0.001 |
| Experimental | *3.29 (1.27, 6.46) | *1.20 (0.77, 2.08) | 5.143 | <0.001 | ||
| CEA (ng/ml, 0-5.00) | Control | *3.12 (2.10, 5.10) | *1.90 (1.3, 4.30) | 2.857 | 0.004 | |
| Experimental | *2.86 (1.43, 5.10) | *1.68 (1.10, 2.78) | 5.208 | <0.001 | ||
| CYRA21-1(ng/ml, 0-3.30) | Control | *3.02 (2.19, 4.07) | *2.07 (1.56, 2.88) | 2.702 | 0.007 | |
| Experimental | *3.01 (1.74, 3.93) | *2.16 (1.47, 3.15) | 3.069 | 0.002 | ||
| VEGF-A (pg/ml) | Control | +285.44 ± 53.25 | +264.18 ± 49.24 | 4.183 | <0.001 | |
| Experimental | 295.64 ± 73.44 | 273.13 ± 65.60 | 3.030 | 0.004 |
*Median and quaternary values (P25, P75). ^mean ± standard deviation.
+Before and after treatment, t test was used to analyze VEGF-A levels in the two groups, and there was no statistical difference between the two groups (P > 0.05).